Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://journals.lww.com/immunotherapy-journal/abstract/2012/06000/sequential_immunotherapy_by_vaccination_with.3.aspx, but it redirected us to https://journals.lww.com/immunotherapy-journal/abstract/2012/06000/sequential_immunotherapy_by_vaccination_with.3.aspx. The analysis below is for the second page.

Title[redir]:
Journal of Immunotherapy
Description:
n on T lymphocytes is associated with enhanced antitumor immunity in animal models of cancer and in patients with advanced melanoma. We hypothesized that sequential therapy with granulocyte-macrophage–colony-stimulating factor (GM-CSF)–expressing whole–glioma-cell vaccination and CTLA-4 blockade is an effective strategy for treating established intracranial gliomas. GL261 glioma cells were injected into the right frontal lobes of syngeneic C57/BL6 mice. At days 3, 6, and 9 after tumor implantation, mice were treated with subcutaneous injection of irradiated GM-CSF–expressing GL261 cells. Mice were also treated with intraperitoneal injection of anti-CTLA-4 monoclonal antibodies (mAbs), either at days 3, 6, and 9 or days 12, 15, and 18. Animals were followed for survival. Splenocytes were harvested at day 22 for use in enzyme-linked immunosorbent spot assays. Early treatment of established intracranial gliomas with high-dose CTLA-4 blockade was associated with increased survival in GL261-bearing mice. Later treatment with anti-CTLA-4 monoclonal antibodies did not significantly improve survival compared with control-treated mice. Early vaccination followed by subsequent CTLA-4 blockade was associated with significantly improved survival versus either treatment alone and intensified tumor-specific immunity as measured by interferon-γ enzyme-linked immunosorbent spot assay. Sequential immunotherapy with GM-CSF–expressing irradiated glioma cells and CTLA-4 blockade synergistically prolongs survival in mice bearing established intracranial gliomas....

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Games

Content Management System {📝}

What CMS is doi.org built with?


Doi.org operates using MYBB.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 76,504,851 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We're unsure if the website is profiting.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Doi.org could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

journal, survival, ctla, blockade, mice, issue, immunotherapy, vaccination, gmcsfexpressing, glioma, cells, established, intracranial, access, subscribe, alerts, authors, abstract, sequential, gliomas, days, treatment, log, register, logo, articles, advanced, issues, buy, effective, immunity, treated, injection, irradiated, antictla, monoclonal, antibodies, enzymelinked, immunosorbent, spot, early, significantly, text, subscribers, request, browse, content, submit, service, privacy,

Topics {✒️}

granulocyte-macrophage–colony-stimulating factor gm-csf–expressing glioma cells high-dose ctla-4 blockade anti-ctla-4 monoclonal antibodies syngeneic c57/bl6 mice established intracranial gliomas intensified tumor-specific immunity gl261 glioma cells subsequent ctla-4 blockade gl261-bearing mice antibody-based blockade full text access journal authors submit enhanced antitumor immunity gm-csf glioma-cell vaccination short median survival advanced melanoma artificial intelligence training ctla-4 blockade etoc alerts control-treated mice service request 800-638-3030 register subscribe individual subscribers log journal tables issue sequential immunotherapy prolonging survival sequential therapy tumor implantation increased survival website subscribe journal expressing center submit incurable disease clinical trials possibly effective ctla-4 animal models effective strategy frontal lobes subcutaneous injection intraperitoneal injection email inbox rights reserved data mining early vaccination early treatment

Questions {❓}

  • Not a Subscriber?

Social Networks {👍}(1)

External Links {🔗}(58)

Analytics and Tracking {📊}

  • Comscore
  • Google Analytics
  • Google Tag Manager

Libraries {📚}

  • Bootstrap
  • FontAwesome
  • jQuery
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Cookielaw
  • Jsdelivr
  • Scite
  • Wolterskluwer

5.31s.